Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Immunome stock (Immunome)

Buy Immunome stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Immunome is a biotechnology business based in the US. Immunome shares (IMNM) are listed on the NASDAQ and all prices are listed in US Dollars. Immunome employs 62 staff and has a trailing 12-month revenue of around $12.7 million.

Our top picks for where to buy Immunome Inc stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Immunome stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – IMNM. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Immunome stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Not rated yet
Stocks, ETFs
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
Stocks, ETFs, Cryptocurrency
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Immunome stock price (NASDAQ: IMNM)

Use our graph to track the performance of IMNM stocks over time.

Immunome shares at a glance

Information last updated 2024-07-14.
Latest market close$14.16
52-week range$6.13 - $30.96
50-day moving average $14.02
200-day moving average $14.45
Wall St. target price$33.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-17.58

Is it a good time to buy Immunome stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immunome price performance over time

Historical closes compared with the close of $14.16 from 2024-07-15

1 week (2024-07-09) 13.28%
1 month (2024-06-14) -5.09%
3 months (2024-04-16) -23.04%
6 months (2024-01-16) 1.65%
1 year (2023-07-14) 82.24%
2 years (2022-07-15) 260.31%
3 years (2021-07-16) 15.52
5 years (2019-07-12) N/A

Immunome financials

Revenue TTM $12.7 million
Gross profit TTM $0
Return on assets TTM -15.16%
Return on equity TTM -154.98%
Profit margin 0%
Book value $4.78
Market Capitalization $809 million

TTM: trailing 12 months

Immunome share dividends

We're not expecting Immunome to pay a dividend over the next 12 months.

Immunome share price volatility

Over the last 12 months, Immunome's shares have ranged in value from as little as $6.13 up to $30.958. A popular way to gauge a stock's volatility is its "beta".

IMNM.US volatility(beta: 1.79)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immunome's is 1.791. This would suggest that Immunome's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Immunome's beta into context you can compare it against those of similar companies.

Immunome overview

Immunome, Inc. , a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. .

Frequently asked questions

What percentage of Immunome is owned by insiders or institutions?
Currently 17.083% of Immunome shares are held by insiders and 62.296% by institutions.
How many people work for Immunome?
Latest data suggests 62 work at Immunome.
When does the fiscal year end for Immunome?
Immunome's fiscal year ends in December.
Where is Immunome based?
Immunome's address is: 18702 N. Creek Parkway, Bothell, WA, United States, 98011
What is Immunome's ISIN number?
Immunome's international securities identification number is: US45257U1088

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site